10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Health Sciences Acquisitions Corp and Immunovant Sciences, a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases and a member of Switzerland's Roivant family of companies, today announced that they have entered into a definitive share exchange agreement (SEA). 2 October 2019
Japanese drugmaker Asahi Kasei Pharma has filed a complaint requesting a preliminary injunction against Endo Ventures Limited and Endo Pharmaceuticals to require Ireland-incorporated Endo to continue to supply the company with Xiaflex (collagenase clostridium histolyticum), for the treatment of Dupuytren’s contracture. 2 October 2019
Tridek-One, a privately-held French biotech specializing in the development of products for the treatment of immune and inflammatory disorders, has named three new members of its executive team. 2 October 2019
Swiss pharma giant Novartis has presented additional data from the Phase III PREVENT trial on the use of Cosentyx (secukinumab) in non-radiographic axial spondyloarthritis (nr-axSpA). 2 October 2019
Cambridge, USA-based cell and gene therapy specialist ElevateBio has launched a new company, dubbed HighPassBio, dedicated to advancing novel T cell immunotherapies. 1 October 2019
Heron Therapeutics has resubmitted its New Drug Application (NDA) to the US Food and Drug Administration for HTX-011, an investigational agent for the management of postoperative pain. 1 October 2019
Canada’s ImmunoPrecise Antibodies, a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced the appointment of industry professional Dr Stefan Lang as chief business officer (CBO). 1 October 2019
Stockholm’s Calliditas Therapeutics has moved one step closer to securing European Medicines Agency (EMA) approval for its lead compound nefecon, the firm said in a statement on Monday. 1 October 2019
Switzerland-based biotech firm Numab Therapeutics and Japan’s Eisai have initiated a partnership, under a research and option agreement, to discover and develop novel multi-specific antibody immunotherapies for cancer, using Numab’s proprietary MATCH platform. 1 October 2019
Independent French company Servier has acquired Pixuvri (pixantrone), a drug approved in the European Union as monotherapy for multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma, from USA-based CTI BioPharma. 1 October 2019
The Institute for Clinical and Economic Review (ICER) has posted a draft scoping document on its planned review of the cost-effectiveness offered by Vertex Pharmaceuticals’ (Nasdaq: VRTX) cystic fibrosis (CF) drugs in the USA. 1 October 2019
South Korean company Celltrion, which is best known as a biosimilars manufacturer, is about to launch its first innovative product in the USA. 1 October 2019
Sweden’s Moberg Pharma has entered into a license agreement granting Japan’s Taisho Pharmaceutical exclusive Japanese rights to MOB-015, a new topical treatment of onychomycosis based on Moberg's patented proprietary formulation of terbinafine. 1 October 2019
Swiss pharma giant Roche has officially announced localization of two of its innovative drugs in Russia at the facilities of its local partners, reports The Pharma Letter’s local correspondent. 30 September 2019
Positive top-line results from a second Phase III pivotal study evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis (AD), were released on Friday by US pharma giant Pfizer. 30 September 2019
Hutchison China MediTech, also known as Chi-Med, has presented the results of the Phase III study of surufatinib in advanced neuroendocrine tumors – extra-pancreatic (SANET-ep) at the 2019 ESMO congress, which met the pre-defined primary endpoint of progression free survival (PFS) early. 30 September 2019
The US Food and Drug Administration has approved Rituxan (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in pediatric patients two years of age and older. 28 September 2019
US biotech G1 Therapeutics has presented preliminary overall survival (OS) data from its Phase II trial of trilaciclib in combination with chemotherapy for the treatment of metastatic triple-negative breast cancer. 28 September 2019
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024